Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
about
Genetically engineered mouse models of Parkinson's diseasePathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body diseaseTargeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic miceTime course and progression of wild type α-synuclein accumulation in a transgenic mouse model.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease.High Throughput Sequencing Identifies MicroRNAs Mediating α-Synuclein Toxicity by Targeting Neuroactive-Ligand Receptor Interaction Pathway in Early Stage of Drosophila Parkinson's Disease Model.Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinAntibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseTranscriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies.Molecular changes in the postmortem parkinsonian brain.Animal models of α-synucleinopathy for Parkinson disease drug development.Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain.β-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors.Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease.Overstimulation of glutamate signals leads to hippocampal transcriptional plasticity in hamsters.Enhanced motivation to alcohol in transgenic mice expressing human α-synuclein.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.Improved spatial learning is associated with increased hippocampal but not prefrontal long-term potentiation in mGluR4 knockout mice.
P2860
Q26852964-774C856A-156B-4CFE-B586-919A08C0B7A2Q26853610-2608DCA1-828B-42AB-BC67-8AC4FCD1A208Q27324174-6AA47BA8-59D7-410A-813B-C3BC1887E552Q27334377-366B52CB-0228-4101-9909-E23D8E767503Q30532478-BB145E23-68F4-4CF3-A942-C6D7BFA00656Q30650119-1A438EBC-6AFC-4CAE-BE47-06ECAEA93463Q33865366-42E55AAF-FD0A-406B-B6FC-2AB11EB9F275Q34287848-BE3F4850-4C2D-4BA6-9945-47438658603BQ35771016-0F6A6989-C9A7-42DE-86B5-E6B4C431D53EQ35786733-4BD00B24-0EC9-477E-93A8-3A93CDE17789Q36608855-97ECFDB6-CC82-4D6B-9111-18C02721AE4AQ36658992-F1E6F379-633B-42F4-BBDD-9468CD3DC8FCQ37117527-BD91EC9F-4FBB-4DEC-8F19-0C46C5342446Q38038399-41AD93A2-5877-4B7D-AA65-4B15C7FF173DQ38174986-0ACFC9FB-3419-4D5E-929C-5A84C686F903Q38218083-EE7012D5-F08F-4241-A771-FF03F556F460Q38435692-B1514564-5183-49FA-89B4-C25EC277BCD3Q38887346-01A4BD1E-B734-4382-B6D3-AC8B89F60F62Q40106906-F78036A2-A16C-4F45-9157-1805CB89B87FQ40150743-BFA73C21-41A6-4E05-ADBB-1DD906EBC2AEQ41117719-19BF1857-39E5-4623-9E2C-98D5BBB1B09EQ41468480-B02982D7-C79B-4253-A02D-4ADD818B5366Q42461333-90388C37-695C-4CFD-856A-3A2565E2D50FQ44979915-4FA3C1FA-A836-4707-9392-8A9FA67BFC68Q46047010-1FE33724-98DB-482C-BBD2-706299B8C35AQ46931246-2123AEB0-09B2-4A6A-870D-FF390F0BB08BQ47325206-641051C0-FE0A-4793-9D3C-C6F2BEA998F7Q47619917-36B03890-4299-4F78-83FE-85758460F46CQ49357267-0CF7DEEF-98A1-4759-B2F5-77460BAAA44DQ50313262-DC3CCC14-AE17-4138-B073-18C73D441253
P2860
Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@ast
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@en
type
label
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@ast
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@en
prefLabel
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@ast
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@en
P2093
P2860
P50
P1433
P1476
Alterations in mGluR5 expressi ...... plications for excitotoxicity.
@en
P2093
Anna Cartier
Brian Spencer
Christina Patrick
David Askay
Diana L Price
Mark H Ellisman
Natalie MacLean-Lewis
P2860
P304
P356
10.1371/JOURNAL.PONE.0014020
P407
P577
2010-11-16T00:00:00Z